PCM
ABBV icon

Palisade Capital Management’s AbbVie ABBV Stock Holding History

Palisade Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Buy
71,165
+677
+1% +$150K 0.52% 70
2025
Q4 		$16.1M Buy
70,488
+2,116
+3% +$482K 0.48% 79
2025
Q3 		$15.8M Buy
68,372
+625
+0.9% +$127K 0.43% 84
2025
Q2 		$12.6M Sell
67,747
-335
-0.5% -$62.3K 0.36% 89
2025
Q1 		$14.3M Sell
68,082
-1,084
-2% -$211K 0.41% 87
2024
Q4 		$12.3M Buy
69,166
+168
+0.2% +$30.9K 0.33% 100
2024
Q3 		$13.6M Buy
68,998
+24
+0% +$4.48K 0.36% 93
2024
Q2 		$11.8M Buy
68,974
+807
+1% +$134K 0.32% 100
2024
Q1 		$12.4M Sell
68,167
-17,424
-20% -$3M 0.33% 101
2023
Q4 		$13.3M Sell
85,591
-200
-0.2% -$29.2K 0.35% 96
2023
Q3 		$12.8M Sell
85,791
-123
-0.1% -$18.1K 0.36% 95
2023
Q2 		$11.6M Sell
85,914
-2,555
-3% -$375K 0.31% 102
2023
Q1 		$14.1M Sell
88,469
-11,868
-12% -$1.81M 0.38% 89
2022
Q4 		$16.2M Sell
100,337
-4,607
-4% -$706K 0.44% 77
2022
Q3 		$14.1M Sell
104,944
-1,723
-2% -$247K 0.4% 84
2022
Q2 		$16.3M Sell
106,667
-899
-0.8% -$137K 0.44% 77
2022
Q1 		$17.4M Sell
107,566
-2,597
-2% -$377K 0.4% 87
2021
Q4 		$14.9M Buy
110,163
+39,773
+57% +$4.7M 0.3% 106
2021
Q3 		$7.59M Buy
70,390
+362
+0.5% +$41.4K 0.17% 168
2021
Q2 		$7.89M Buy
70,028
+3,270
+5% +$368K 0.18% 156
2021
Q1 		$7.22M Buy
66,758
+2,513
+4% +$269K 0.17% 165
2020
Q4 		$6.88M Buy
64,245
+2,355
+4% +$226K 0.18% 169
2020
Q3 		$5.42M Buy
61,890
+6,095
+11% +$574K 0.16% 185
2020
Q2 		$5.48M Buy
55,795
+10,097
+22% +$889K 0.17% 179
2020
Q1 		$3.48M Buy
45,698
+9,848
+27% +$839K 0.12% 220
2019
Q4 		$3.17M Buy
35,850
+3,000
+9% +$249K 0.09% 255
2019
Q3 		$2.49M Buy
32,850
+6,875
+26% +$471K 0.08% 269
2019
Q2 		$1.89M Hold
25,975
– – 0.06% 293
2019
Q1 		$2.09M Sell
25,975
-5,625
-18% -$460K 0.07% 287
2018
Q4 		$2.91M Buy
31,600
+1,925
+6% +$169K 0.11% 229
2018
Q3 		$2.81M Hold
29,675
– – 0.08% 270
2018
Q2 		$2.75M Sell
29,675
-8,645
-23% -$844K 0.08% 267
2018
Q1 		$3.63M Sell
38,320
-145
-0.4% -$15.9K 0.12% 216
2017
Q4 		$3.72M Buy
38,465
+150
+0.4% +$14.1K 0.13% 212
2017
Q3 		$3.4M Buy
38,315
+885
+2% +$67.4K 0.12% 210
2017
Q2 		$2.71M Buy
37,430
+655
+2% +$44K 0.1% 237
2017
Q1 		$2.4M Sell
36,775
-904
-2% -$56.8K 0.09% 242
2016
Q4 		$2.36M Buy
37,679
+585
+2% +$35.7K 0.09% 237
2016
Q3 		$2.34M Buy
37,094
+1,950
+6% +$126K 0.08% 307
2016
Q2 		$2.18M Buy
35,144
+6,155
+21% +$375K 0.08% 319
2016
Q1 		$1.66M Buy
28,989
+614
+2% +$34.2K 0.05% 368
2015
Q4 		$1.68M Buy
28,375
+20,451
+258% +$1.18M 0.05% 362
2015
Q3 		$431K Buy
7,924
+274
+4% +$17.8K 0.01% 472
2015
Q2 		$514K Hold
7,650
– – 0.01% 470
2015
Q1 		$448K Buy
7,650
+4,450
+139% +$269K 0.01% 452
2014
Q4 		$209K Buy
+3,200
New +$202K 0.01% 464

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Palisade Capital Management's ABBV Position: Q1 2026 in Review

Palisade Capital Management increased its AbbVie (ABBV) stake by 0.96% in Q1 2026, buying an estimated $150K and bringing the position to 71,165 shares worth $15.5M. The position accounts for 0.52% of the portfolio, ranked #70.

Palisade Capital Management first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $17.4M in Q1 2022. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Palisade Capital Management held 71,165 shares of AbbVie worth $15.5M as of Q1 2026.
  • Palisade Capital Management bought 677 AbbVie shares in Q1 2026, an estimated $150K.
  • AbbVie made up 0.52% of Palisade Capital Management's portfolio in Q1 2026, its #70 holding.
  • Palisade Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
  • Palisade Capital Management's AbbVie position peaked at $17.4M in Q1 2022.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.